• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now

    6/12/24 7:00:00 AM ET
    $ASPI
    $ATRA
    $CIA
    $CLNN
    Major Chemicals
    Industrials
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ASPI alert in real time by email

    MIAMI, June 12, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 72nd Emerging Growth Conference on June 12 & 13, 2024.

    The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.

    Register for the Conference here.

    Submit Questions for any of the presenting companies to:

    [email protected]

    For updates, follow us on Twitter

    Sponsors:

    QuoteMedia - Keep Investors Informed with Dynamic Plug and Play IR Solutions

    (844) 485-8200

    [email protected]

    www.QuoteMedia.com

    ProCore Advisory - Unleashing the power of strategic investor relations for public and pre-IPO companies

    (832)-847-1327

    [email protected]

    www.procoreadvisory.com

    Day 2

    June 13, 2024

    8:45

    Virtual Lobby opens.

    Register for the Conference. If you already registered, go back to the registration link and click "Already registered" and enter your email.

    9:00

    Introduction

    9:05 - 9:35

    FBR, Ltd. (OTCQB:FBRKF) (ASX: FBR) 

    Keynote speaker: Michael John Pivac, CEO & Managing Director

    9:40 - 10:10

    Huize Holding Limited (NASDQQ: HUIZ)

    Keynote speaker: Mr. Ron Tam, Co CFO

    10:15 - 10:45

    Ascend Wellness Holdings Inc. (OTCQX:AAWH)

    Keynote speaker: Rebecca Koar, EVP of Investor Relations and Strategy

    10:50 – 11:20

    Targa Exploration Corp. (OTCQB:TRGEF) (CSE:TEX)

    Keynote speaker: Cameron Tymstra, President & CEO

      

    11:25 - 11:55

    Sucro Limited (TSXV:SUG) (OTCQB:SUGCF)

    Keynote speaker: Don Hill, Chairman

    12:00 – 12:30

    Patriot AG Corp.

    Keynote speaker: Eric Till, CEO / CFO, & Kyle Severson, COO

    12:35 – 1:05

    Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

    Keynote speaker: Jason Awe, Head of Corporate Communications & IR

    1:10 – 1:40

    Bioxytran, Inc. (OTCQB:BIXT)

    Keynote speakers: David Platt, CEO & Mike Sheikh, Executive Vice President Business Development

      

    1:45 - 2:15

    InMed Pharmaceuticals, Inc. (NASDAQ:INM)

    Keynote speaker: Eric Adams, CEO

    2:20 – 2:30

    Immuron Limited (NASDAQ:IMRN)

    Keynote speaker: Steve Lydeamore, CEO

    2:35 - 2:45

    Citizens, Inc. (NYSE:CIA)

    Keynote speakers: Gerald W. Shields, Vice Chairman and CEO Jeff Conklin, CFO

    2:50 – 3:00

    Digital Brand Media & Marketing Group, Inc. (OTC:DBMM)

    Keynote speaker: Reggie James, COO, Sr. VP & Exec. Director

    3:05 – 3:15

    ATRenew Inc. (NYSE:RERE)

    Keynote speakers: Jessie Jin, Investor Relations Manager & Jeremy Ji, Director of Corporate Development & Investor Relations

    3:20 - 3:30

    Meihua International Medical Technologies Co. (NASDAQ:MHUA)

    Keynote speaker: Mr. Steven Wang, CEO

    3:35 – 3:45

    GTI Energy, Ltd. (OTC:GTRIF) (ASX: GTR)

    Keynote speaker: Bruce Lane, Executive Director, CEO

    Presenting Today, June 12, 2024

    8:45

    Virtual Lobby opens.

    Register for the Conference. If you already registered, go back to the registration link and click "Already registered" and enter your email.

    9:00

    Introduction

    9:05 – 9:35

    Perfect Corp. (NYSE:PERF)

    Keynote speaker: Louis Chen, EVP, CSO

    9:40 - 10:10

    Intellabridge Technology Corporation (OTCQB:KASHF) (CSE:KASH)

    Keynote speaker: John Eagleton, CEO

    10:15 - 10:45

    Pulsar Helium, Inc.'s (OTCQB:PSRHF) (TSXV:PLSR)

    Keynote speaker: Thomas Abraham-James President / CEO

    10:50 - 11:20

    Cadrenal Therapeutics, Inc. (NASDAQ:CVKD)

    Keynote speaker: Mr. Quang X. Pham, Chairman & CEO

    11:25 - 11:55

    LogicMark, Inc. (NASDAQ:LGMK)

    Keynote speaker: Ms. Chia-Lin Simmons, CEO

      

    12:00 - 12:30

    Unusual Machines, Inc. (NYSE:UMAC)

    Keynote speaker: Allan Evans, CEO

    12:35 - 1:05

    SeaStar Medical Holding Corporation (NASDAQ:ICU)

    Keynote speaker: Eric Schlorff, President / CEO, Director

    1:10 - 1:40

    Diakonos Oncology, Inc.

    Keynote speakers: Jay Hartenbach, COO, & Anthony Baldor, CFO & Head of Business Development

    1:45 - 2:15

    Longeveron, Inc. (NASDAQ:LGVN)

    Keynote speaker: Mohamed Wa'el Hashad, CEO & Director

    2:20 - 3:00

    Clene Inc., (NASDAQ:CLNN)

    Keynote speaker: Rob Etherington, President / CEO, & Morgan Grown, CFO

    Postponed to July

    Regen BioPharma Inc. (OTC:RGBP)

    Keynote speakers: David Koos, President / CEO, and Harry M. Lander, Ph.D. Senior Scientific Consultant

    3:20 - 3:30

    SenesTech, Inc. (NASDAQ:SNES)

    Keynote speaker: Joel L. Fruendt, President, CEO, & Director

    3:35 - 4:05

    ASP Isotopes Inc. (NASDAQ:ASPI)

    Keynote speaker: Paul Elliot Mann, CEO

    Visit the following link to register. You will then receive an email containing the link and time to sign into the conference.

    Register for the Conference here.

    Submit Questions for any of the presenting companies to:

    [email protected]

    Replays: Subscribe to our YouTube Channel

    About EmergingGrowth.com

    Founded in 2009, Emerging Growth.com quickly became a leader in its space and has developed an extensive history of identifying emerging growth companies that can be overlooked by the investment community.

    About the Emerging Growth Conference

    The Emerging Growth Conference is an effective way for public companies to engage with the investment community regarding their Company, new products, services and other major announcements from anywhere, in an effective and time efficient manner.

    All sessions are conducted through video webcasts. Our conference serves as a vehicle for Emerging Growth to build relationships with our existing and potential clients.  Accordingly, a certain number of the presenting companies are our current clients, and some may become our clients in the future.  In exchange for services we provide, our clients pay us fees in the form of cash and securities, and we may currently have, or in the future may have investments in the securities of certain of the presenting companies. Finally, certain of the presenting companies have paid us a fee to secure a presentation time slot or to present generally. The presentations to be delivered by the presenting companies (including any virtual handouts of written materials) have not been approved, endorsed by or otherwise reviewed by EmergingGrowth.com nor should they in any way be construed to have been made in connection with an offer to sell or a solicitation of an offer to buy securities. Please consult an investment professional before investing in anything viewed on the Emerging Growth Conference or on EmergingGrowth.com.

    If you believe or know of a company that might fit our audience, contact us here.

    Thank you for your interest in our conference, and we look forward to your participation in future conferences.

    Contact:

    Emerging Growth

    Phone: 1-305-330-1985

    Email: [email protected]



    Primary Logo

    Get the next $ASPI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASPI
    $ATRA
    $CIA
    $CLNN

    CompanyDatePrice TargetRatingAnalyst
    Atara Biotherapeutics Inc.
    $ATRA
    1/13/2026$6.00Buy → Hold
    Canaccord Genuity
    ASP Isotopes Inc.
    $ASPI
    12/4/2025$13.00Overweight
    Cantor Fitzgerald
    Unusual Machines Inc.
    $UMAC
    8/19/2025$15.00Buy
    Needham
    Unusual Machines Inc.
    $UMAC
    12/18/2024$18.00Buy
    Maxim Group
    Longeveron Inc.
    $LGVN
    12/6/2024$10.00Buy
    ROTH MKM
    Perfect Corp.
    $PERF
    10/21/2024$5.00Outperform
    Noble Capital Markets
    ASP Isotopes Inc.
    $ASPI
    10/4/2024$4.50Buy
    Canaccord Genuity
    Cadrenal Therapeutics Inc.
    $CVKD
    12/18/2023$4.00Outperform
    Noble Capital Markets
    More analyst ratings

    $ASPI
    $ATRA
    $CIA
    $CLNN
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by SenesTech Inc.

    SCHEDULE 13G/A - SenesTech, Inc. (0001680378) (Subject)

    2/2/26 5:26:13 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    ASP Isotopes Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - ASP Isotopes Inc. (0001921865) (Filer)

    1/30/26 5:00:39 PM ET
    $ASPI
    Major Chemicals
    Industrials

    SEC Form SCHEDULE 13G filed by ASP Isotopes Inc.

    SCHEDULE 13G - ASP Isotopes Inc. (0001921865) (Subject)

    1/30/26 1:28:15 PM ET
    $ASPI
    Major Chemicals
    Industrials

    $ASPI
    $ATRA
    $CIA
    $CLNN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program

    The Mikaela Naylon Give Kids a Chance Act reauthorizes the Pediatric Priority Review Voucher (PPRV) Program and extends eligibility for medicines achieving U.S. FDA approval before September 2029The Pediatric Priority Review Voucher program encourages the development of treatments for rare pediatric diseasesU.S. FDA has awarded Longeveron's laromestrocel Hypoplastic Left Heart Syndrome (HLHS) program Rare Pediatric Disease designation, Orphan Drug designation, and Fast Track designationWith the extension of the PPRV Program, Longeveron may be granted a Priority Review Voucher if laromestrocel's Biological License Application (BLA) is approved by the FDA before September 2029 MIAMI, Feb. 05

    2/5/26 9:15:00 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perfect Corp. Partners with Nicole Miller at Fashion Forward Week to Bring Iconic Archival Collections to Life Through an AI Virtual Fitting Room

    The immersive experience will leverage Perfect Corp.'s industry-leading Generative AI Perfect Corp. (NYSE:PERF), the global leader in AI- and AR-powered beauty and fashion technology, today announced a partnership with legendary American fashion designer Nicole Miller at the second edition of Fashion Forward Week. Together, they will debut an immersive, AI-powered virtual fitting room that allows attendees to digitally try on Nicole Miller's iconic archival designs using Perfect Corp.'s next-generation Generative AI Clothing Try-On technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260204992204/en/Perfect Corp. Partner

    2/4/26 8:00:00 AM ET
    $PERF
    Computer Software: Prepackaged Software
    Technology

    Perfect Corp. Partners with Make Over at ParagonCorp's Beauty Science Tech 2026 to Deliver AI-Powered Beauty Personalization, Alongside Skin Analysis API Integration

    Powered by Perfect Corp.'s enterprise Face Attribute analysis and Virtual Try-On technologies, alongside its Skin Analysis API, ParagonCorp delivered professional-grade beauty personalization to millions across Indonesia. Perfect Corp. (NYSE:PERF), the leading AI and AR beauty and fashion technology provider, brought next-generation beauty tech to Jakarta, partnering with Make Over, the professional makeup brand under Indonesia's largest beauty company, ParagonCorp, for Beauty Science & Technology (BST) 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260202987563/en/Perfect Corp. Partners with Make Over at ParagonCorp's B

    2/4/26 2:18:00 AM ET
    $PERF
    Computer Software: Prepackaged Software
    Technology

    $ASPI
    $ATRA
    $CIA
    $CLNN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Atara Biotherapeutics downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Atara Biotherapeutics from Buy to Hold and set a new price target of $6.00

    1/13/26 10:16:38 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cantor Fitzgerald initiated coverage on ASP Isotopes with a new price target

    Cantor Fitzgerald initiated coverage of ASP Isotopes with a rating of Overweight and set a new price target of $13.00

    12/4/25 8:40:44 AM ET
    $ASPI
    Major Chemicals
    Industrials

    Needham initiated coverage on Unusual Machines with a new price target

    Needham initiated coverage of Unusual Machines with a rating of Buy and set a new price target of $15.00

    8/19/25 8:37:18 AM ET
    $UMAC
    Radio And Television Broadcasting And Communications Equipment
    Technology

    $ASPI
    $ATRA
    $CIA
    $CLNN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Glenbrook Capital Management bought $94,524 worth of shares (48,138 units at $1.96) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/3/26 5:27:37 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Director Matlin David J bought $216,664 worth of shares (33,333 units at $6.50), increasing direct ownership by 7% to 477,824 units (SEC Form 4)

    4 - Clene Inc. (0001822791) (Issuer)

    1/13/26 2:48:54 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Baird Jennifer A bought $987 worth of shares (4,200 units at $0.24), increasing direct ownership by 13% to 36,200 units (SEC Form 4)

    4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

    12/22/25 6:55:38 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    $ASPI
    $ATRA
    $CIA
    $CLNN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Schneider Carine

    4 - LogicMark, Inc. (0001566826) (Issuer)

    2/5/26 4:35:54 PM ET
    $LGMK
    Industrial Specialties
    Health Care

    SEC Form 4 filed by Director Pettitt John P

    4 - LogicMark, Inc. (0001566826) (Issuer)

    2/5/26 4:35:10 PM ET
    $LGMK
    Industrial Specialties
    Health Care

    SEC Form 4 filed by Director Curtis Robert Arthur

    4 - LogicMark, Inc. (0001566826) (Issuer)

    2/5/26 4:34:49 PM ET
    $LGMK
    Industrial Specialties
    Health Care

    $ASPI
    $ATRA
    $CIA
    $CLNN
    Leadership Updates

    Live Leadership Updates

    View All

    SenesTech Announces CEO Transition Plan

    Board To Initiate Search For New Leadership As Current CEO Plans Retirement Dr. Jamie Bechtel Named Interim Executive Chair To Further Support Transition PHOENIX, Jan. 28, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a pioneer in fertility control solutions for managing rodent populations, today announced that Joel Fruendt, President and Chief Executive Officer, has informed the Board of Directors of his intent to retire. The Board will commence a formal search for a successor. Mr. Fruendt will continue to serve as President and CEO until the search is completed or until June 30, 2026, whichever occurs first.

    1/28/26 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors

    PONTE VEDRA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today announced the appointment of Lee Scott Golden, M.D., to its Board of Directors, effective immediately. Dr. Golden will serve as an independent director. Dr. Golden currently serves as Executive Vice President and Chief Medical Officer at PTC Therapeutics, Inc. (NASDAQ:PTCT), where he leads global clinical development across a broad rare disease pipeline. Before joining PTC, Dr. Golden served as the Chief Medical Officer at Espero BioPharma, Inc., a development-stage card

    12/1/25 9:00:00 AM ET
    $CVKD
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SeaStar Medical Announces Appointment of Michael Messinger as CFO

    DENVER, Nov. 17, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that Michael Messinger, a seasoned healthcare executive with over 25 years of industry experience, has joined SeaStar Medical as Chief Financial Officer. "Mike brings to SeaStar Medical a breadth of financial expertise, operational discipline, and strategic healthcare experience that will be invaluable as we grow our commercial operations and prepare for additional commercial opportunities for our SCD therapy," stated Eric Schlorff, CE

    11/17/25 8:43:00 AM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    $ASPI
    $ATRA
    $CIA
    $CLNN
    Financials

    Live finance-specific insights

    View All

    Dominari Holdings Issues Letter to Shareholders

    NEW YORK, Jan. 28, 2026 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) ("Dominari" or the "Company") today issued the following letter to shareholders: I am pleased to report that 2025 was a transformative and highly successful year for Dominari. Through disciplined execution, expanded distribution capabilities, and a focus on high-growth opportunities across both public and private markets, we delivered strong financial performance and created substantive shareholder value. Shareholder Value Creation As we began 2025, the Company's stock price was just over $1.00. When

    1/28/26 8:30:00 AM ET
    $DOMH
    $TZUP
    $UMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    EDP Services
    Technology

    Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)

    U.S. Food and Drug Administration has issued a Complete Response Letter (CRL) Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the EBVALLO™ (tabelecleucel) Biologics License Application (BLA) as monotherapy treatment for adult and pediatric patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), who have received at least one

    1/12/26 8:00:00 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)

    Novel first-in-class therapeutic targeting a key immune signaling pathway and the underlying cause of HITIt is the first and only potent, highly selective inhibitor of human 12-LOX in clinical testing, distinguishing it from related compounds.Orphan Drug and Fast Track designations from the FDA PONTE VEDRA, Fla., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of current anticoagulation therapy, today announced the acquisition of VLX-1005 and related 12-lipoxygenase (12-LOX) assets from Veralox Therapeutics ("Veralox"). The acquisition immediately strengthens Cadren

    12/11/25 8:05:00 AM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASPI
    $ATRA
    $CIA
    $CLNN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by LogicMark Inc.

    SC 13D/A - LogicMark, Inc. (0001566826) (Subject)

    12/3/24 3:35:39 PM ET
    $LGMK
    Industrial Specialties
    Health Care

    Amendment: SEC Form SC 13G/A filed by SenesTech Inc.

    SC 13G/A - SenesTech, Inc. (0001680378) (Subject)

    11/14/24 7:28:08 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Amendment: SEC Form SC 13G/A filed by SenesTech Inc.

    SC 13G/A - SenesTech, Inc. (0001680378) (Subject)

    11/14/24 7:12:23 PM ET
    $SNES
    Agricultural Chemicals
    Industrials